PG2
Phase 2Small molecule
PG2 is one of 51 small molecule programs targeting Fatigue. It is currently in Phase 2.
3
Indications
7
Total Trials
0
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
461 competitors in Stroke
#DrugCompanyPhaseTrials
1Activase
RochePreclinical
PG2
PPhytoHealth Corporation
Phase 2
Zometa
PfizerPreclinical
Folvite
Eli LillyPreclinical
Proamatine
TakedaPreclinical
Repatha
AmgenPreclinical
Pradaxa
Boehringer IngelheimPreclinical
Alka-Seltzer
AAbbott
Preclinical
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Direct Anticoagulant
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Fatigue3 trials
Stroke2 trials
PG2 Injection 500 mg in Acute Stroke Study (Pass)
Completed·—·Phase 2·NCT01603667·86 enrolled
Thrombocytopenic Purpura1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PG2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- PPhytoHealth Corporation